Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

Russian Familial Hypercholesterolemia RegistryRecruiting
NCT02208869N/AUpdated Nov 2, 2022
Sponsor: Russian Cardiology Research and Production Center
Familial Hypercholesterolemia
Russia
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.Completed
NCT00830466Phase 1Updated Nov 1, 2022
Sponsor: University of California, Irvine
Port Wine Stain
United States
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.Completed
NCT00800722Phase 1Updated Nov 1, 2022
Sponsor: University of California, Irvine
Port Wine Stain
United States
Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTsCompleted
NCT04353466NAUpdated Oct 28, 2022
Sponsor: Shaare Zedek Medical Center
Gaucher Disease, Type 1
A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.Completed
NCT01323270Phase 2Updated Oct 27, 2022
Sponsor: Pfizer
Meningococcal Vaccine · rLP2086 · Repevax · N Meningitidis Serogroup B
Finland, Germany, Poland
A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 YearsCompleted
NCT01299480Phase 2Updated Oct 27, 2022
Sponsor: Pfizer
Meningococcal Vaccine
Czechia, Denmark, Finland, Germany, Poland +2 more
The STEPP Study: Sensors To Evaluate Physical PerformanceCompleted
NCT03952767NAUpdated Oct 25, 2022
Sponsor: UNC Lineberger Comprehensive Cancer Center
Oncology
United States
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant ChemotherapyCompleted
NCT04130152EARLY_Phase 1Updated Oct 25, 2022
Sponsor: SOLTI Breast Cancer Research Group
Breast Cancer
Spain
A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast CancerCompleted
NCT02448771Phase 1, Phase 2Updated Oct 24, 2022
Sponsor: Dana-Farber Cancer Institute
Breast Cancer Stage IV · Unresectable Locally Advanced Invasive Breast Cancer · Metastatic Invasive Breast Cancer
United States
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid ArthritisCompleted
NCT00883896Phase 2Updated Oct 21, 2022
Sponsor: Pfizer
Rheumatoid Arthritis
United States, Belgium, Colombia, Croatia, Germany +6 more
VXM01 Plus Avelumab Combination Study in Progressive GlioblastomaUnknown
NCT03750071Phase 1, Phase 2Updated Oct 20, 2022
Sponsor: Vaximm GmbH
Recurrent Glioblastoma
Germany
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMENCompleted
NCT04032093Phase 2Updated Oct 18, 2022
Sponsor: Pfizer
Respiratory Tract Infection
United States, Argentina, Chile, New Zealand, South Africa
Prospective Observational Epidemiologic Study of Maraviroc's SafetyCompleted
NCT00665561N/AUpdated Oct 18, 2022
Sponsor: ViiV Healthcare
Human Immunodeficiency Virus
United States, Belgium, Brazil, Canada, France +6 more
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell CarcinomaTerminated
NCT00520533Phase 1Updated Oct 12, 2022
Sponsor: Ludwig Institute for Cancer Research
Renal Cell Carcinoma (RCC)
Australia
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient SubjectsUnknown
NCT05569928NAUpdated Oct 10, 2022
Sponsor: Marcello Arca
Familial Hypobetalipoproteinemia · Familial Hypobetalipoproteinemia - Heterozygous Form
Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y AntigenTerminated
NCT00293215Phase 1Updated Oct 10, 2022
Sponsor: Ludwig Institute for Cancer Research
Neoplasms
Australia
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in TaiwanCompleted
NCT00688870Phase 3Updated Oct 7, 2022
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Vaccines · Pneumococcal Conjugate Vaccine
Taiwan
Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 DiabetesCompleted
NCT01586442Phase 3Updated Oct 7, 2022
Sponsor: Montreal Heart Institute
Heart Failure · Type 2 Diabetes · Glucose Intolerance
Canada
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)Completed
NCT04516291Phase 2Updated Oct 4, 2022
Sponsor: Pfizer
Dyslipidemias · Hyperlipidemias · Hyperlipoproteinemias
United States, Canada, Poland
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring AnticoagulationCompleted
NCT02981472Phase 2Updated Oct 3, 2022
Sponsor: Bristol-Myers Squibb
Thrombosis
United States, Argentina, Australia, Austria, Brazil +9 more
BRaziLian outcomE for metAStatic breasT CancerUnknown
NCT05559528N/AUpdated Sep 29, 2022
Sponsor: Hospital do Coracao
Metastatic Breast Cancer · Breast Cancer Stage IV
Brazil
InO - A Retrospective Study of UK Patients With LeukaemiaCompleted
NCT04456959N/AUpdated Sep 28, 2022
Sponsor: Pfizer
Precursor Cell Lymphoblastic Leukemia-Lymphoma
United Kingdom
Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative DementiasUnknown
NCT02921477Phase 1Updated Sep 28, 2022
Sponsor: Neurological Associates of West Los Angeles
Mild Cognitive Impairment · Dementia
United States
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)Completed
NCT02933697Phase 3Updated Sep 27, 2022
Sponsor: Atrial Fibrillation Network
Atrial Fibrillation · End-stage Kidney Disease
Germany
Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)Completed
NCT01986881Phase 3Updated Sep 23, 2022
Sponsor: Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus

Previous page Next page